Literature DB >> 9140746

Assessment of the preferred plane and sequence in the depiction of mesial temporal sclerosis using magnetic resonance imaging.

L C Meiners1, J Valk, P G van Gils, G A de Kort, T D Witkamp, L M Ramos, A C van Huffelen, C W van Veelen, G H Jansen, H J Wynne, W P Mali.   

Abstract

RATIONALE AND
OBJECTIVES: Definition of optimal magnetic resonance (MR) scanning plane and conventional MR sequence for the detection of mesial temporal sclerosis (MTS).
METHODS: Coronal and axial T2-weighted images and axial T2-weighted images parallel to the long axis of the hippocampus (APLAH) and coronal inversion recovery (IR) images were obtained in patients with medically intractable temporal lobe epilepsy in their phase 1 preoperative evaluation. Thirty-three consecutive MR scans were reviewed by a panel of three radiologists. Twenty-three patients had MR abnormalities consistent with MTS, and ten scans were normal. To assess the best single scanning technique, another group of three radiologists, who were masked to all patient data, individually assessed the different planes and sequences of the 33 studies presented separately in a random fashion. For each plane and sequence, the likelihood (L) ratio for the correct diagnosis was determined separately.
RESULTS: For all planes considered separately, a likelihood ratio of 4.4 was optimal for the coronal T2-weighted images. The likelihood ratio of APLAH T2 was 2.2; of axial T2, 3.9; of coronal IR, indefinite because of 100% specificity.
CONCLUSIONS: For the assessment of MTS, coronal T2-weighted images were considered the best single scanning technique.

Entities:  

Mesh:

Year:  1997        PMID: 9140746     DOI: 10.1097/00004424-199705000-00003

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  1 in total

1.  Assessment of the preferred scout sagittal orientation for temporal lobe imaging with magnetic resonance.

Authors:  P M Gonçalves Pereira; E Oliveira; M F Secca
Journal:  MAGMA       Date:  2004-12-03       Impact factor: 2.310

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.